

07.11.2019

- 14:00 - 17:00 Molecular pathology and single cell analysis: New technologies coming to practise** **Abbey room**
- Moderation: J. Haanen¹, F. André², C. Swanton³, ¹Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR, ³Translational Cancer Therapeutics Department, The Francis Crick Institute, London, GB
- 14:00 - 14:30 **Digital pathology: Emerging technologies in the field**
J. Adam, Institut Gustave Roussy, Villejuif, FR
- 14:30 - 15:00 **How to analyse data from digital pathology**
T. Graham, Barts Cancer Institute-Queen Mary University of London, London, GB
- 15:00 - 15:30 **Mass cytometry: Principles and applications**
S. Tietscher, UZH - University of Zurich - Irchel Campus, Zurich, CH
- 15:30 - 16:00 **Coffee break**
- 16:00 - 16:30 **Basics of single cell sequencing**
F. Ginhoux, A*STAR - Singapore Immunology Network (SIgN), Singapore, SG
- 16:30 - 17:00 **Bioinformatics and mathematics to analyse single cell data**
C. Ng, University of Bern, Bern, CH

08.11.2019

08:40 - 08:50 Welcome from the Chairs Fleming room

08:40 - 08:50 **Welcome to MAP 2019**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

08:50 - 10:30 Molecular target/Disease orientation Fleming room
Moderation: F. André, Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR

08:50 - 09:10 **Pancreatic cancer**
A. Biankin, University of Glasgow - Wolfson Wohl Cancer Research Centre - Institute of Cancer Sciences, Bearsden, GB

09:10 - 09:30 **Glioblastomas**
R. Verhaak, Jackson Laboratory for Genomic Medicine, Farmington, US

09:30 - 09:50 **Biliary tract cancer**
L. Goyal, Massachusetts General Hospital, Boston, US

09:50 - 10:10 **Sarcoma**
J.-Y. Blay, Centre Léon Bérard, Lyon, FR

10:10 - 10:20 **Proffered paper presentation I**

10:20 - 10:30 **Proffered paper presentation II**

10:30 - 11:00 Coffee break Britten room

11:00 - 12:20	Clonal evolution	Fleming room
	Moderation: S. Turajlic, Royal Marsden Hospital NHS Foundation Trust, London, GB	
11:00 - 11:20	Tracking evolution in prostate cancer with cfDNA profiling	
	<u>G. Attard</u> , University College London Cancer Institute, London, GB	
11:20 - 11:40	Tweaking DNA repair pathways to improve cancer immune surveillance	
	<u>A. Bardelli</u> , Istituto di Candiolo - FPO - IRCCS, Candiolo, IT	
11:40 - 12:00	Clonal evolution of metastatic disease	
	<u>S. Turajlic</u> , Royal Marsden Hospital NHS Foundation Trust, London, GB	
12:00 - 12:10	Proffered paper presentation III	
12:10 - 12:20	Proffered paper presentation VI	
12:30 - 13:15	Industry satellite symposium	Fleming room
13:15 - 14:00	Lunch and poster viewing	Britten room
14:00 - 15:30	Transforming imaging into predictors	Fleming room
	Moderation: F. André, Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR	
14:00 - 14:20	Artificial Intelligence (AI) in radiology	
	<u>H. Aerts</u> , Harvard Medical School, Boston, US	
14:20 - 14:40	Radiomics to predict sensitivity to immunotherapeutics	
	<u>E. Deutsch</u> , Institut Gustave Roussy, Villejuif, FR	
14:40 - 15:00	Digital multiplexed pathology	
	<u>I. Wistuba</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
15:00 - 15:20	Computational tools to interpret multiplexed pathology	
	<u>L. Keren</u> , Stanford University, Stanford, US	
15:20 - 15:30	Q&A	

15:30 - 16:15 **Gordon Peters Memorial Keynote** **Fleming room**
Moderation: C. Swanton, Translational Cancer Therapeutics Department, The Francis Crick Institute, London, GB

15:30 - 16:15 **Myc and microenvironment**

G. Evan, University of Cambridge, Cambridge, GB

16:15 - 16:40 **Coffee break** **Britten room**

16:40 - 18:00 **Immuno - (Prediction of therapy and response)** **Fleming room**

Moderation: J. Haanen, Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

16:40 - 17:00 **Revealing the cellular degradome**

Y. Merbl, Weizmann Institute of Science, Rehovot, IL

17:00 - 17:20 **Predicting antigen presentation**

M. Bassani-Sternberg, Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, CH

17:20 - 17:40 **Combining antigen presentation and T cell recognition to reveal immune responses**

Y. Samuels, Weizmann Institute of Science, Rehovot, IL

17:40 - 18:00 **Unbiased high throughput identification of tumour-reactive TCRs from TIL**

W. Scheper, The Netherlands Cancer Institute, Amsterdam, NL

09.11.2019

08:30 - 10:00 **Single cell analysis / single cell sequencing** **Fleming room**

Moderation: J. Haanen, Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

08:30 - 08:50 **Subclonal heterogeneity and behaviour in TNBC**

L. Ellisen, Massachusetts General Hospital, Boston, US

08:50 - 09:10 **Paracrine signalling controls IFN α production by plasmacytoid DC**

J. De Vries, Radboud University Medical Centre Nijmegen, Nijmegen, NL

09:10 - 09:30 **Clonal diversity of the T cell repertoire in lung cancer**

S. Quezada, University College London, London, GB

09:30 - 09:50 **TET2 and DNA methylation in hematopoietic transformation**

O. Bernard, Gustave Roussy - Cancer Campus, Villejuif, FR

09:50 - 10:00 **Proffered paper presentation V**

10:00 - 10:30 **Coffee break** **Britten room**

10:30 - 12:00 Germline susceptibility Fleming room
Moderation: C. Turnbull, The Institute Of Cancer Research, The Institute of Cancer Research (ICR), London, GB

10:30 - 10:50 **Interpretation of germline variation in cancer susceptibility genes: Pitfalls and challenges**
C. Turnbull, The Institute of Cancer Research (ICR), London, GB

10:50 - 11:10 **Emerging management paradigms in syndromes of high penetrance susceptibility: TP53 as an exemplar case**
H. Hanson, St George's Hospital NHS Trust, London, GB

11:10 - 11:30 **Polygenic genomic profiling: Cancer risk prediction in the population - Opportunity versus hype**
P. Pharoah, University of Cambridge-Public Health and Primary Care, Cambridge, GB

11:30 - 11:50 **Integration of analyses of the germline and the tumour for optimal patient management**
A. George, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

11:50 - 12:00 **Q&A**

12:05 - 12:50 Industry satellite symposium Fleming room
12:50 - 13:30 Lunch Britten room
13:30 - 14:15 Targeting cancer neoantigens Fleming room
Moderation: C. Swanton, Translational Cancer Therapeutics Department, The Francis Crick Institute, London, GB

13:30 - 14:15 **Targeting cancer neoantigens**
U. Sahin, BioNTech AG, Mainz, DE

14:15 - 15:30 Biomarkers and checkpoint inhibitor Fleming room

Moderation: S. Turajlic¹, F. André², ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR

14:15 - 14:35 Predictive biomarkers for the efficacy of anti-PD(L)1: Which biomarkers for daily use?

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

14:35 - 14:55 Predictive biomarkers for the efficacy of IO: What's in the pipeline

D. Thommen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:55 - 15:05 Proffered paper presentation VI

15:05 - 15:15 Proffered paper presentation VII

15:15 - 15:30 Discussion

15:30 - 16:00 Coffee break Britten room

16:00 - 17:30 Targeting the PI3K pathway in human epithelial malignancies' Fleming room
Moderation: C. Caldas, Oncology, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

16:00 - 16:20 **Assessing the PI3K pathway in breast cancer: How best to stratify patients**
C. Caldas, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

16:20 - 16:40 **Health and disease activating PI3K**
B. Vanhaesebroeck, UCL - University College London, London, GB

16:40 - 17:00 **Targeting the PI3K pathway: Trials and tribulations**
L. Friedman, Genentech Inc. - Roche - USA, South San Francisco, US

17:00 - 17:20 **Predictive markers of PIK3CA efficacy**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

17:20 - 17:30 **Proffered paper presentation VIII**